Tozinameran

{
  "id": "MLC-T-ONC-017281",
  "term": "Tozinameran",
  "field": "Oncology and biomedicine",
  "definition": "A formulation consisting of lipid nanoparticle (LNP) encapsulating a nucleoside modified messenger RNA (modRNA) encoding an optimized form of the full-length severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of tozinameran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.",
  "synonyms": [
    "BNT1162b2 SARS-CoV-2 vaccine",
    "BNT162b2 COVID-19 vaccine",
    "Pfizer-BioNTech COVID-19 vaccine",
    "SARS-CoV-2 SP mRNA LNP vaccine BNT162b2"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tozinameran/"
}